Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused due to alteration in gene sequence coding for dystrophin proterin, which is present the muscle. It is a rare muscle disease which majorly affects males. The symptoms includes intellectual disability, muscle weakness and, difficulty in walking and breathing. Congestive heart failure, mental impairment, pneumonia or respiratory failure are some of the complications of this disease. The treatment is available to control or reduce the signs and symptoms as DMD is not curable. Steroid drugs are used to control the symptoms of duchenne muscular dystrophy. Stem cell therapy and gene therapy could be used for treatment of this disease in future.
Growing investments in the research and development, to find out effective treatment for DMD is driving the growth of duchenne muscular dystrophy (DMD) treatment market
According to the reports of Centers for Disease Control and prevention (CDC) 2007, 349 out of 2.37 million males in the United States were reported to be suffering from DMD. Whereas in 2019, 349 new cases of DMD were reported. Increasing incidences of DMD and requirement for its treatment is driving the growth of duchenne muscular dystrophy treatment market. Various organizations are involved in spreading awareness and investing in research and development to find the effective treatment for this disease, which is contributing to the growth of duchenne muscular dystrophy treatment market. For instance, Muscular Dystrophy Association (MDA), U.S. invests 75000 USD in research and development to find out the treatment for duchenne muscular dystrophy and the association funds more than 150 care centers, health care facility centers, and hospitals across U.S. and other countries. Moreover, other factors, such as constant research on stem cell therapy, gene therapy, and exon skipping drugs for the treatment of DMD is expected to propel the growth of DMD treatment market. However, major restraints hampering the growth of duchenne muscular dystrophy treatment market are, low seeking rate due to prognosis and late diagnosis of this disease.
Rising hospitalization for DMD is the factor helping the hospital segment to hold the maximum share in duchenne muscular dystrophy (DMD) treatment market
The global duchenne muscular dystrophy (DMD) treatment market is segmented by therapy, by product type, by end users, and by regions.
On the basis of type of therapy, the Duchenne muscular dystrophy (DMD) treatment market is segmented into
On the basis of product type, the duchenne muscular dystrophy (DMD) treatment market is segmented into
On the basis of end-users, the duchenne muscular dystrophy (DMD) treatment market is segmented into
Growing patient population in North America and Europe is the factor contributing to the growth of duchenne muscular dystrophy (DMD) treatment market in these regions
Regional segmentation of Duchenne muscular dystrophy (DMD) treatment market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America dominates in the duchenne muscular dystrophy treatment market, due well-established healthcare facilities in this region. Europe contributes to the growth of duchenne muscular dystrophy treatment market followed by North America, due to high rate of affected population in this region. For instance, according to Center for Disease Control and Prevention (CDC), in North England, 233 out of 1.49 million male patients were reported for DMD or other muscular dystrophy cases in 2009.
Key players are involved in the research and development of novel drug therapy for the treatment of duchenne muscular dystrophy (DMD)
Key players operating duchenne muscular dystrophy (DMD) treatment market includes SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics, Pfizer Incorporated, Pharmacia & Upjohn LLC, and others. Major industry players are involved in the research and development of novel drugs for treatment, and strategies such as collaboration and partnership are adopted by companies to hold the major share in the duchenne muscular dystrophy (DMD) treatment market. For instance, PTC Therapeutics International Limited has obtained conditional approval and orphan drug designation in 2014 for Translarna, which is a novel gene therapy for the treatment of duchenne muscular dystrophy.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.